Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by wildbird1on Aug 20, 2018 10:38am
210 Views
Post# 28486164

Two years ago...

Two years ago...1) Two years ago, Genenews didn't have a working billing process.
To solve the problem in 2016 Genenews joined force with JTS.

Question?..Why did it take so long to get the billing process functional.
Peoples have no idea how complex and laborious it is to implement a billing process that include 5 levels.
Level no 1 = The patient.
   ''          2 = The doctor office.
   ''          3 = The insurance companies.
   ''          4 = The healthcare system.
   ''          5 = Finally the worst of the worst , Government agency.....
5 Levels = a lots of bugs to work out, that is why it was only restarted in May 2018.

2) Two years ago Genenews didn't have a big distribution network.
To solve the problem in May 2018 Genenews joined force with AIM Laboratory big distribution network.

3) Two years ago Genenews didn't have a Chief Commercial Officer.
To solve the problem in July 2018 Genenews appointed David Byram as CCO.
When a Chief Commercial Officer come on boar, it is usually because sales and commercial operation are expected to grow.

4) Two years ago Genenews didn't have the necessary expertise to fully develop and market its cancer tests.
To solve the problem Genenews joined force with LifeX who has impressive experiences in bringing to market hight potential products.

Optimistic predictions...
For those that argue that Jame Tripp in the past made predictions that were to optimistic...Big deal..every single CEO that strongly beleive in his product (his baby) has a tendency to be overly optimistic.

You have to agree that Jame Tripp rely more and more on peoples with good expertise in their fielf of knowledge ( JTA, AIM Laboratories, LifeX).

As you can see this is not the same company that it was two years ago, not even the same as it was three months ago.
May, 2018... Restart of the billing process.
May, 2018...AIM laboratories big distribution network.
July, 2018...new Chief Commercial Officer to oversee sale and commercial operations.
August, 2018... LifeX with its impressive experience in bringing to market hight potential products.

The results of these very recents change in operation should be felf in the next few financial.


Bullboard Posts